Fig. 3: Targeted inhibition of PTGDS by AT56 displayed anti-tumor effects in DLBCL. | Cell Death & Differentiation

Fig. 3: Targeted inhibition of PTGDS by AT56 displayed anti-tumor effects in DLBCL.

From: Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of Wnt–β-catenin–STAT3 signaling

Fig. 3

A AT56 inhibited the production of PGD2 in DLBCL cells. B AT56 suppressed cell viability in sh-Con cells, but not in sh-PTGDS cells. C and D AT56 decreased cell proliferation and c-myc expression in DLBCL cells. E and F AT56 induced G0/G1 cell cycle arrest and decreased expression of Cyclin D1 and CDK2 in DLBCL cells. G-H. AT56 induced cell apoptosis and regulated the expression of apoptosis-associated proteins. I and J AT56 suppressed cell invasion and the expression of zeb1 and vimentin. K–M Nude mice with AT56 treatment (80 mg/kg) displayed decreased tumor growth rate, weight, and volume. N AT56 treatment regulated the expression of important proteins in mice tumor tissues. Data are shown as the mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.

Back to article page